GlassScriptPhysician profile
Michelle Corle
NPI 1033662770
$13,090.29
in general payments reported to CMS, 2019-2025
46 companies · $2,272 in 2025
The $2,272 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,532 · 2022: $3,415 · 2023: $2,206 · 2024: $2,666 · 2025: $2,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,932 · Travel and Lodging: $192 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,931.64 |
| Travel and Lodging | $191.81 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,773.75 | 2021-2025 | |
| Pfizer INC. | $1,025.89 | 2021-2025 | |
| Boston Scientific Corporation | $657.05 | 2022-2025 | Watchman Flx, Watchman |
| Lilly USA, LLC | $591.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $588.96 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $555.16 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $472.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.87 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $442.07 | 2021-2025 | Repatha, Otezla, Tezspire |
| E.R. Squibb & Sons, L.L.C. | $427.36 | 2021-2024 | Eliquis |
| Abbott Laboratories | $415.90 | 2021-2024 | Freestyle Libre 3, Eterna |
| Phathom Pharmaceuticals, INC. | $368.15 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $359.81 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.05 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $290.11 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $264.27 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $261.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.02 | 2021-2025 | |
| Exact Sciences Corporation | $148.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $122.17 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Impel Pharmaceuticals INC. | $113.40 | 2023 | Trudhesa |
| Lundbeck LLC | $106.42 | 2023-2025 | Rexulti |
| Inari Medical, INC. | $105.86 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Otsuka America Pharmaceutical, INC. | $105.14 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $94.03 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $87.20 | 2023-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $83.33 | 2021-2025 | |
| Allergan, INC. | $72.55 | 2022 | |
| Tactile Systems Technology INC | $66.96 | 2024 | Entre Plus, Flexitouch Plus |
| Alexion Pharmaceuticals, INC. | $58.39 | 2021-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $58.11 | 2021-2022 | |
| Amarin Pharma, INC. | $52.22 | 2021-2022 | |
| Abiomed | $42.39 | 2025 | |
| Aimmune Therapeutics, INC. | $35.51 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $30.54 | 2021 | |
| Mannkind Corporation | $21.04 | 2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $19.26 | 2023 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $19.16 | 2023 | Uptravi, Opsumit |
| Nestle Healthcare Nutrition INC. | $17.32 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.84 | 2022 | |
| Dexcom, INC. | $15.06 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2021 | |
| Sanofi Pasteur INC. | $12.92 | 2022 | |
| Eisai INC. | $12.83 | 2023 | |
| Biogen, INC. | $11.78 | 2021 | |
| Horizon Therapeutics Plc | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Corle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.